A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
Mita MM, Rowinsky EK, Forero L, Eckhart SG, Izbicka E, Weiss GR, Beeram M, Mita AC, de Bono JS, Tolcher AW, Hammond LA, Simmons P, Berg K, Takimoto C, Patnaik A.
Mita MM, et al. Among authors: weiss gr.
Cancer Chemother Pharmacol. 2007 Feb;59(2):165-74. doi: 10.1007/s00280-006-0255-0. Epub 2006 May 31.
Cancer Chemother Pharmacol. 2007.
PMID: 16736151
Clinical Trial.